CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for trial patients. New predictive and prognostic biomarkers validated in the general mCRC population are needed. Caudal-type homeobox 2 (CDX2) is an intestine-specific transcription factor with potential p...

Full description

Bibliographic Details
Main Authors: Kristine Aasebø, Anca Dragomir, Magnus Sundström, Artur Mezheyeuski, Per-Henrik Edqvist, Geir Egil Eide, Fredrik Ponten, Per Pfeiffer, Bengt Glimelius, Halfdan Sorbye
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
caudal type homeobox transcription factor
CDX2
colorectal cancer
metastatic disease
stage 4 colorectal cancer
prognosis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00008/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00008/full

Similar Items